mRNA – Pharma’s Next Rising Star?
The future of vaccines is not just about Covid-19
Chief Investment Office27 Jan 2023
  • The pandemic of 2020 highlighted the revenue potential of vaccines for pharmaceutical companies
  • The proliferation of respiratory illnesses & advances in mRNA tech could usher in vaccine golden age
  • Growing R&D spend by Big Pharma will drive a strong pipeline of vaccine products and patent arsenal
  • We continue to favour Big Pharma within the healthcare sector
Article image
Photo credit: Unsplash
Read More

A new golden age for vaccines? It has been nearly three years since Covid-19 turned the world on its head. And while the existential threat posed by the pandemic is no longer as acute as it once was, it continues to impact our lives in very real ways, chief among which is the need to be inoculated. This saw vaccines being developed in record speed in 2020 and transform hitherto unknown companies like BioNTech and Moderna into household names. As vaccination rates continue to climb globally, and Covid inches closer towards becoming endemic, the total pie for said vaccines will inevitably shrink.

However, that does not mean pharmaceutical companies are seeing the end of the vaccine party. Quite the opposite, vaccine-related revenues are set to increase moving forward with the debut of commercial Covid-19 vaccines, which are expected to cost significantly higher per dose. Additionally, 2023 is likely see the advent of the first messenger-RNA (mRNA) vaccines for Influenza and respiratory syncytial virus (RSV), which will emerge as new revenue streams of existing vaccine makers. Market participants are betting on a big year for vaccine makers and pharmaceutical companies, as evidenced by the stellar performance of the healthcare sector.



Covid-19 vaccines to go commercial in 2023. Since the onset of the pandemic, vaccine costs have been borne chiefly by governments. However, this is set to change as the market transitions from a public to a private one, welcoming commercial Covid-19 vaccines on board this year. Accordingly, vaccine prices are expected to increase significantly; Pfizer has already stated that it could price its commercial vaccines between USD110 and USD130 per dose, while Moderna expects a price between USD64 and USD100. In comparison, the US government has been paying much lower thus far, approximately USD30 per dose for Pfizer’s vaccine and about USD26 for Moderna’s. While commercial vaccines and their higher prices will not fully offset the reduction in revenue from slowing demand, they will help Covid-19 products remain indispensable to pharmaceutical companies. Pfizer chief executive Albert Bourla expects that their Covid-19 franchise will remain a multibillion dollar recurring revenue generator for the foreseeable future.

Continue to favour Big Pharma within the healthcare sector. Healthcare remains one of our top investment themes, and within the sector we continue to favour Big Pharma as they:

  1. Have a globally diversified revenue stream
  2. Possess the resources and expertise to conduct R&D and ensure patent protection, which will in turn contribute to commercial exclusivity and pricing power
  3. Have the balance sheet strength to acquire prominent industry peers to ensure a continuous pipeline
  4. Are trading at reasonable valuations


Download the PDF to read the full report.

Topic

Note: All views expressed are current as at the stated date of publication

DISCLAIMERS AND IMPORTANT NOTES

This information herein is published by DBS Bank Ltd. (“DBS Bank”) and is for information only.  This publication is intended for DBS Bank and its subsidiaries or affiliates (collectively “DBS”) and clients to whom it has been delivered and may not be reproduced, transmitted or communicated to any other person without the prior written permission of DBS Bank. 

This publication is not and does not constitute or form part of any offer, recommendation, invitation or solicitation to you to subscribe to or to enter into any transaction as described, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction for cash or other consideration and should not be viewed as such.

The information herein may be incomplete or condensed and it may not include a number of terms and provisions nor does it identify or define all or any of the risks associated to any actual transaction. Any terms, conditions and opinions contained herein may have been obtained from various sources and neither DBS nor any of their respective directors or employees (collectively the “DBS Group”) make any warranty, expressed or implied, as to its accuracy or completeness and thus assume no responsibility of it. The information herein may be subject to further revision, verification and updating and DBS Group undertakes no responsibility thereof.

All figures and amounts stated are for illustration purposes only and shall not bind DBS Group. This publication does not have regard to the specific investment objectives, financial situation or particular needs of any specific person. Before entering into any transaction to purchase any product mentioned in this publication, you should take steps to ensure that you understand the transaction and has made an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances. In particular, you should read all the relevant documentation pertaining to the product and may wish to seek advice from a financial or other professional adviser or make such independent investigations as you consider necessary or appropriate for such purposes. If you choose not to do so, you should consider carefully whether any product mentioned in this publication is suitable for you.  DBS Group does not act as an adviser and assumes no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any arrangement or entrance into any transaction in reliance on the information contained herein.  In order to build your own independent analysis of any transaction and its consequences, you should consult your own independent financial, accounting, tax, legal or other competent professional advisors as you deem appropriate to ensure that any assessment you make is suitable for you in light of your own financial, accounting, tax, and legal constraints and objectives without relying in any way on DBS Group or any position which DBS Group might have expressed in this document or orally to you in the discussion.

Any information relating to past performance, or any future forecast based on past performance or other assumptions, is not necessarily a reliable indicator of future results.

If this publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of the Information, which may arise as a result of electronic transmission. If verification is required, please request for a hard-copy version.

This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

If you have received this communication by email, please do not distribute or copy this email. If you believe that you have received this e-mail in error, please inform the sender or contact us immediately. DBS Group reserves the right to monitor and record electronic and telephone communications made by or to its personnel for regulatory or operational purposes. The security, accuracy and timeliness of electronic communications cannot be assured.

Singapore: This publication is distributed by DBS Bank Ltd (Company Regn. No. 196800306E) (“DBS”) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore (the “MAS”).

Indonesia: This publication is distributed by PT Bank DBS Indonesia (DBSI). DBSI is licensed and supervised by the Indonesia Financial Services Authority (OJK) and a member of the Indonesia Deposit Insurance Corporation (LPS). This publication is not and does not constitute or form part of any offer, recommendation, invitation, or solicitation to you to subscribe to or to enter into any transaction as described, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction for cash or other consideration and should not be viewed as such.

India: This publication is distributed by DBS Bank India Ltd. (“DBIL”) and is on “as is” basis and for information only. This publication is not intended to be source of advice in respect of the material presented or information published, and shall not be construed to be legal, tax, financial or investment advisory. This document is not, and should not be construed as, an offer, invitation, recommendation, or solicitation to enter into any transaction in relation to any of the products and services mentioned herein. DBIL does not make any warranty of any kind, express or implied, including but not limited to warranties of completeness, accuracy of information, merchantability, or fitness for a particular purpose.